Comparison of the EORTC QLQ‐BM22 and the BOMET‐QOL quality of life questionnaires in patients with bone metastases. Issue 2 (1st April 2013)

• Record Type: Journal Article
• Authors: Bedard, Gillian; Zeng, Liang; Poon, Michael; Lam, Henry; Lauzon, Natalie; Chow, Edward
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 10:Issue 2(2014:Jun.)
• Page Start: 118
• Page End: 123
• Publication Date: 2013-04-01
• Subjects: Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.12064
• Languages: English
• ISSNs: 1743-7555

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <sec id="ajco12064-sec-0001" sec-type="section"> <title>Aims</title> <p>Bone metastases are a common complication of advanced cancer and often result in a decrease in patients' quality of life. Very few specific modules have been created to accurately assess quality of life in this patient group. The purpose of this study was to compare two questionnaires, the European Organization for Research and Treatment of Cancer quality of life questionnaire for patients with bone metastases (EORTC QLQ‐BM22) and the bone metastases quality of life questionnaire (BOMET‐QOL.</p> </sec> <sec id="ajco12064-sec-0002" sec-type="section"> <title>Methods</title> <p>A literature search was conducted in Medline, Health and Psychosocial Instruments, Embase and Embase Classic to identify studies that discussed the development, validation and reliability of the (EORTC) QLQ‐BM22 and the BOMET‐QOL. Studies that discussed the development and validity of the questionnaire along with studies using these tools were included.</p> </sec> <sec id="ajco12064-sec-0003" sec-type="section"> <title>Results</title> <p>Both questionnaires were developed in collaboration with patients and health‐care professionals. The QLQ‐BM22 is over twice the length of the BOMET‐QOL, with 22 questions as compared to 10. The QLQ‐BM22 has four subscales while the BOMET‐QOL has no subscales. The QLQ‐BM22 gives a more in‐depth analysis of symptoms and well‐being and includes issues such as mobility, side effects, complications of treatment and dependency. The BOMET‐QOL is shorter and gives an overall assessment of pain and mobility. Scoring, item format, organization and response options vary between the questionnaires but the recall period for both is the previous week. Both questionnaires have been determined valid and reliable.</p> </sec> <sec id="ajco12064-sec-0004" sec-type="section"> <title>Conclusion</title> <p>The QLQ‐BM22 and the BOMET‐QOL are designed specifically for patients with bone metastases and each has strengths and weaknesses. Use of one over the other is ultimately dependent on trial design and investigators' goals.</p> </sec> </abstract>